Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Consensus Rating of “Hold” from Analysts

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Rating) have earned a consensus recommendation of “Hold” from the sixteen ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $27.23.

A number of research analysts have issued reports on the stock. Canaccord Genuity Group reduced their target price on shares of Intercept Pharmaceuticals from $31.00 to $29.00 and set a “hold” rating for the company in a research note on Tuesday, March 8th. Needham & Company LLC dropped their price target on shares of Intercept Pharmaceuticals from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 3rd. B. Riley boosted their price target on shares of Intercept Pharmaceuticals from $30.00 to $32.00 in a research report on Tuesday. StockNews.com initiated coverage on shares of Intercept Pharmaceuticals in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Finally, Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $14.00 price target on the stock in a report on Monday, March 7th.

NASDAQ ICPT traded up $0.44 on Monday, reaching $17.88. The stock had a trading volume of 856,998 shares, compared to its average volume of 1,444,229. The stock has a fifty day moving average price of $16.61 and a two-hundred day moving average price of $16.47. Intercept Pharmaceuticals has a 12-month low of $11.60 and a 12-month high of $22.36.

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) last posted its quarterly earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.31. During the same quarter last year, the business earned ($1.22) earnings per share. Analysts anticipate that Intercept Pharmaceuticals will post -2.71 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Moors & Cabot Inc. bought a new position in Intercept Pharmaceuticals during the 3rd quarter valued at about $751,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Intercept Pharmaceuticals by 63.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,879 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 1,903 shares during the last quarter. Running Point Capital Advisors LLC bought a new stake in shares of Intercept Pharmaceuticals during the first quarter worth approximately $163,000. Ensign Peak Advisors Inc bought a new stake in shares of Intercept Pharmaceuticals during the fourth quarter worth approximately $180,000. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Intercept Pharmaceuticals during the first quarter worth approximately $186,000. Institutional investors and hedge funds own 83.44% of the company’s stock.

About Intercept Pharmaceuticals (Get Rating)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.

Featured Articles